Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases

US8231874B2 · kind B2 · utility

Inventors

• John Leonard · Manchester, US
• Samuel Goldman · Acton, US
• Richard O'Hara · Quincy, US

Key dates

• Filing date: Jul 28, 2011
• Grant date: Jul 31, 2012
• Expiry date: Jul 28, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/76
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-γ or TNF-α. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.